Verano Holdings (VRNO) Cash & Equivalents (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Cash & Equivalents of $74.0 million for Q1 2026, down 12.1% year-over-year from $84.2 million in Q1 2025, and down 10.51% quarter-over-quarter from $82.7 million in Q4 2025.
Verano Holdings (VRNO) Cash & Equivalents (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Cash & Equivalents for 6 consecutive years, with $74.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 12.1% year-over-year to $74.0 million; the TTM figure through Mar 2026 stood at $74.0 million (down 12.1% YoY), while the FY2025 annual figure was $82.7 million, down 5.78% from the prior year.
- Cash & Equivalents fell to $74.0 million in Q1 2026 per VRNO's latest filing, from $82.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $193.8 million in Q1 2024 and bottomed at $65.0 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $101.6 million across 5 years, with a median of $86.3 million in 2022.
- Annual changes were most pronounced in 2023 — Cash & Equivalents soared 105.96% — and 2025, when it plunged 56.54%.
- Verano Holdings' Cash & Equivalents stood at $84.9 million in 2022, then jumped by 105.96% to $174.8 million in 2023, then plunged by 49.76% to $87.8 million in 2024, then dropped by 5.78% to $82.7 million in 2025, then retreated by 10.51% to $74.0 million in 2026.
- Business Quant data shows VRNO's Cash & Equivalents at $74.0 million in Q1 2026, $82.7 million in Q4 2025, and $82.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | Verano Holdings | 440.28 Mn | 355.08 Mn | 99.70 Mn | 85.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.20 Mn |
| Mar 31, 2026 | 74.03 Mn |
| Dec 31, 2025 | 82.72 Mn |
| Sep 30, 2025 | 82.62 Mn |
| Jun 30, 2025 | 68.57 Mn |
| Mar 31, 2025 | 84.22 Mn |
| Dec 31, 2024 | 87.80 Mn |
| Sep 30, 2024 | 64.98 Mn |
| Jun 30, 2024 | 130.05 Mn |
| Mar 31, 2024 | 193.80 Mn |
| Dec 31, 2023 | 174.76 Mn |
| Sep 30, 2023 | 129.92 Mn |
| Jun 30, 2023 | 102.58 Mn |
| Mar 31, 2023 | 95.13 Mn |
| Dec 31, 2022 | 84.85 Mn |
| Sep 30, 2022 | 76.42 Mn |
| Jun 30, 2022 | 92.83 Mn |
| Dec 31, 2021 | 99.12 Mn |